Eertink, Jakoba J. http://orcid.org/0000-0002-6094-0016
Zwezerijnen, Gerben J. C. http://orcid.org/0000-0002-9571-9362
Cysouw, Matthijs C. F. http://orcid.org/0000-0001-5946-0173
Wiegers, Sanne E. http://orcid.org/0000-0003-3698-8121
Pfaehler, Elisabeth A. G. http://orcid.org/0000-0002-6160-3011
Lugtenburg, Pieternella J. http://orcid.org/0000-0002-6735-8651
van der Holt, Bronno http://orcid.org/0000-0001-6414-2671
Hoekstra, Otto S. http://orcid.org/0000-0003-0767-2734
de Vet, Henrica C. W. http://orcid.org/0000-0002-5454-2804
Zijlstra, Josée M. http://orcid.org/0000-0003-1074-5922
Boellaard, Ronald http://orcid.org/0000-0002-0313-5686
Funding for this research was provided by:
KWF Kankerbestrijding (#VU 2018-11648)
Article History
Received: 9 March 2022
Accepted: 14 July 2022
First Online: 4 August 2022
Declarations
:
: The HOVON-84 study was approved by the Institutional Review Board of the Erasmus MC (2007–055) and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All individual participants included in the HOVON-84 study gave written informed consent to participate in the study.
: Not applicable.
: JJE, MCFC, GJCZ, SEW, EAGP, BvdH, HCWdV, OSH, and RB declare no competing financial interests. PJL received research funding from Takeda, Servier, and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, and Incyte. JMZ received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, and Roche.